A microemulsion of emamectin-ethyl multikinetic salt compound, its preparation method and application

Abstract

The application discloses a microemulsion of emamectin benzoate-ethopropis and a preparation method and application thereof. The microemulsion comprises, in percentage by mass, 2.5-8 wt% of ethopropis, 2-6 wt% of emamectin benzoate, 10-25 wt% of a non-ionic emulsifier, 3-12 wt% of an anionic emulsifier, 10-20 wt% of a strong polar solvent, 10-18 wt% of a weak polar solvent, 1.5-2 wt% of an antioxidant and the balance of water. The microemulsion has a particle size of about 5 nm, excellent dilution stability, hot storage stability and cold storage stability, and has a significant control effect on lepidopteran larvae, coleopteran and thysanopteran pests, with a control effect of more than 88% on the seventh day after application, and low active ingredient consumption, environmental protection and safety.

Description

Technical Field

[0001] This invention relates to the field of pesticide formulation technology, specifically to a microemulsion of abamectin-ethyl spinosad compound, its preparation method, and its application in the control of agricultural pests. Background Technology

[0002] Emamectin benzoate (abbreviated as "emamectin salt") is a new type of highly efficient semi-synthetic antibiotic insecticide synthesized from the fermentation product emamectin B1. It has stomach poison, contact killing and strong penetrating effects, and combines the characteristics of biological pesticides such as ultra-high efficiency, low toxicity, low residue and pollution-free. It has extremely high insecticidal activity against lepidopteran pests such as bollworm, mites, coleopteran and homoptera pests, and is one of the mainstream insecticides widely used in the market.

[0003] Ethyl spinosad (code name XDE-175) is a novel spinosad insecticide produced by fermentation of the actinomycete Saccharomyces polyspora. It acts on nicotinic acetylcholine receptors and γ-aminobutyric acid receptors in the insect nervous system, and has stomach poison and contact effects. It is mainly used to control pests such as lepidopteran larvae, thrips and leaf miners, and has high safety for non-target organisms.

[0004] Although abamectin and spinosad belong to different insecticides with different mechanisms of action, their combination exhibits a significant synergistic effect, broadening the insecticidal spectrum and delaying the development of insecticide resistance in pests. However, abamectin contains unsaturated double bonds and benzoate groups in its molecular structure, making it highly susceptible to decomposition under light, heat, and oxidizing conditions. Spinosad, on the other hand, is sensitive to temperature and free radicals, and is easily degraded and inactivated during formulation processing and storage. When the two are combined, if the solvent system is not properly selected or the emulsifier is not properly matched, not only will a stable, transparent microemulsion system fail to be obtained, but they may also accelerate each other's decomposition, leading to a significant decrease in the content of the active ingredient in a short period of time, thus compromising efficacy. Summary of the Invention

[0005] The purpose of this invention is to provide a microemulsion of abamectin and spinosad, which exhibits good stability. Accordingly, this invention also provides a method for preparing the above-mentioned microemulsion and its application in the control of agricultural pests.

[0006] The specific technical solution of the present invention is as follows: A microemulsion of emamectin benzoate and spinosad, comprising the following components by weight percentage: Ethyl spinosad 2.5-8wt%, abamectin 2-6wt%, nonionic emulsifier 10-25wt%, anionic emulsifier 3-12wt%, strong polar solvent 10-20wt%, weak polar solvent 10-18wt%, and antioxidant 1.5-2wt%, with the balance being water; The nonionic emulsifier is selected from at least two of the following: phenethylphenol polyoxypropylene polyoxyethylene block polymer 1601, castor oil polyoxyethylene ether nonionic emulsifier Emulpon CO 360, nonionic hydroxyl polyethylene oxide block copolymer Ethylan NS-500LQ, polyoxyethylene ether nonionic emulsifier YUS-CP120, Tween 80, isomeric alcohol ether Genapol XM 060, and arylphenol ethoxylated compound Emulsogen TS 200; The anionic emulsifier is selected from at least one of calcium dodecylbenzenesulfonate 500#, hexadecyl polyoxyethylene polyoxypropylene ether phosphate Crodafos C10 / 5A and phosphate ester 1010; The highly polar solvent is selected from at least two of the following: alcohol derivative SV-92, ester-amide RHODIASOLV POLARCLEAN, acetone glycerol Sunamul ACM, carbonate mixture ARMID FMPC, and polyol ester HY-4; The weakly polar solvent is selected from at least one of N,N-dimethyldecanoamide 4296, isooctyl lactate X-EHL, and octadecanamide 4166; The antioxidant is a hindered phenolic antioxidant.

[0007] The above technical solution uses a combination of a specific strongly polar solvent and a weakly polar solvent. The weakly polar solvent in the microemulsion plays a dual role in regulating the rigidity of the oil-water interface film and acting as a hydrophobic barrier. During dilution, the introduction of a large amount of water dilutes the surfactant concentration in the system, leading to a decrease in the strength of the interface film and causing the active ingredients originally encapsulated within the oil core to break down and crystallize. The weakly polar solvent, due to its strong hydrophobicity, accumulates on the inner side of the oil / water interface film, effectively reducing the transmembrane permeation rate of water molecules by increasing the hydrophobic packing density of the hydrocarbon chains in the interface film. This physical barrier slows down the rapid mixing of the external aqueous phase and the internal oil phase, thereby significantly inhibiting crystallization.

[0008] The above technical solution uses a combination of specific nonionic and anionic emulsifiers. The nonionic emulsifier, through its polyoxyethylene chains, extends into the aqueous phase to form a steric hindrance layer, hindering the approach and coalescence of droplets. The anionic emulsifier, after ionization at the interface, imparts a negative charge to the droplet surface, forming an electrostatic repulsion layer, thereby enhancing the mutual repulsion between droplets. The combination of these two types of emulsifiers synergistically reduces interfacial tension and improves the stability of the microemulsion droplet interfacial film.

[0009] In some preferred embodiments, the antioxidant is at least one selected from 2,6-di-tert-butyl-p-cresol, butylated hydroxytoluene, butylated hydroxyanisole, tert-butylhydroquinone, and propyl gallate, preferably 2,6-di-tert-butyl-p-cresol.

[0010] In some preferred embodiments, the nonionic emulsifier is phenylethylphenol polyoxypropylene polyoxyethylene block polymer 1601, nonionic hydroxyl polyethylene oxide block copolymer Ethylan NS-500LQ, and Tween 80.

[0011] In some preferred embodiments, the nonionic emulsifiers are nonionic hydroxyl polyethylene oxide block copolymers Ethylan NS-500LQ and Tween 80.

[0012] In some preferred embodiments, the nonionic emulsifier is an arylphenol ethoxylated compound Emulsogen TS 200, a nonionic hydroxyl polyethylene oxide block copolymer Ethylan NS-500LQ, and an isomeric alcohol ether Genapol XM 060.

[0013] In some preferred embodiments, the nonionic emulsifier is polyoxyethylene ether nonionic emulsifier YUS-CP120, castor oil polyoxyethylene ether nonionic emulsifier Emulpon CO 360, and Tween 80.

[0014] In some preferred embodiments, the highly polar solvent is an alcohol derivative SV-92 and a carbonate mixture ARMID FMPC.

[0015] In some preferred embodiments, the highly polar solvents are acetone glycerol (Sunamul ACM) and ester-amide (RHODIASOLV POLARCLEAN). In some preferred embodiments, the highly polar solvents are polyol esters HY-4 and ester-amides RHODIASOLVPOLARCLEAN.

[0016] In some preferred embodiments, the highly polar solvent is a mixture of polyol ester HY-4 and carbonate ARMIDFMPC.

[0017] In some preferred embodiments, the content of ethyl spinosad is 2.5 wt%, 3 wt%, 5 wt%, or 8 wt%.

[0018] In some preferred embodiments, the content of abamectin is 2 wt%, 5 wt%, 5.7 wt%, or 6 wt%.

[0019] In some preferred embodiments, the content of the nonionic emulsifier is 10 wt%, 14 wt%, 17 wt%, or 25 wt%.

[0020] In some preferred embodiments, the content of the anionic emulsifier is 3 wt%, 8 wt%, 8.5 wt%, or 12 wt%.

[0021] In some preferred embodiments, the content of the strongly polar solvent is 10 wt%, 15 wt%, 15.5 wt%, or 20 wt%.

[0022] In some preferred embodiments, the content of the weakly polar solvent is 10 wt% or 18 wt%.

[0023] In some preferred embodiments, the antioxidant content is 1.5 wt% or 2 wt%.

[0024] In some preferred embodiments, the microemulsion comprises, by weight percentage: 2.5 wt% ethyl spinosad, 5.7 wt% emamectin benzoate, 14 wt% nonionic emulsifier, 8.5 wt% anionic emulsifier, 15.5 wt% strongly polar solvent, 10 wt% weakly polar solvent, and 1.5 wt% antioxidant, with the balance being water. Among them, the nonionic emulsifiers are polyoxyethylene ether nonionic emulsifier YUS-CP120, Tween 80 and castor oil polyoxyethylene ether nonionic emulsifier Emulpon CO 360 with a mass ratio of 1:1:5. The anionic emulsifier is hexadecyl polyoxyethylene polyoxypropylene ether phosphate Crodafos C10 / 5A; The highly polar solvent is ARMID FMPC, a mixture of polyol ester HY-4 and carbonates in a mass ratio of 2.1:1. The weakly polar solvent is N,N-dimethyldecanoamide 4296; The antioxidant is 2,6-di-tert-butyl-p-cresol.

[0025] The preparation method of the above microemulsion includes the following steps: Dissolve abamectin and spinosad in a mixed solution of a strong polar solvent and a weak polar solvent, then add an antioxidant, a nonionic emulsifier and an anionic emulsifier and mix well. Finally, add water and mix well to obtain the final product.

[0026] Application of the above-mentioned microemulsions or microemulsions prepared by the above-mentioned methods in the control of agricultural pests.

[0027] In some preferred embodiments, agricultural pests include lepidopteran larvae, coleopteran pests, and tsioptera pests.

[0028] In some preferred embodiments, the total amount of abamectin and spinosad is 7-10 g / ha.

[0029] According to the above technical solution, the present invention has at least the following beneficial effects: 1. The microemulsion of the present invention, through the compounding of specific strong polar solvents and weak polar solvents, ensures the full dissolution of emamectin benzoate and spinosad ethyl, and prevents crystallization after dilution, providing a suitable oil phase composition for microemulsion formation; the compounding of specific anionic and nonionic emulsifiers reduces interfacial tension and makes the interfacial film of the microemulsion more stable, enabling the system to form microdroplets of about 5 nm and maintain a dispersed state; the antioxidant, in synergy with the specific solvents and emulsifiers, inhibits the oxidative degradation of emamectin benzoate and spinosad ethyl during storage; the synergistic effect of the above components enables the microemulsion provided by the present invention to simultaneously possess excellent emulsion stability, thermal storage stability, and cold storage stability.

[0030] 2. This invention provides a microemulsion of abamectin and spinosad, which has a better pest control effect than existing products that use abamectin or spinosad alone.

[0031] 3. The strong polar solvent and the weak polar solvent used in this invention are both environmentally friendly solvents, and the overall formulation has the characteristics of being environmentally friendly, safe and low-cost. Attached Figure Description

[0032] Figure 1 The images show the state of Examples 4, Comparative Examples 2 and 3 after being diluted 200 times in standard hard water and left to stand for 24 hours. Detailed Implementation

[0033] To enable those skilled in the art to better understand the technical solutions of the present invention, some non-limiting embodiments are further disclosed below to provide a more detailed description of the present invention.

[0034] It is important to note that, in the context of this invention, all figures disclosed herein are approximate values, regardless of whether words such as "approximately" or "about" are used. The value of each figure may vary by 1%, 2%, 5%, 7%, 8%, 10%, 15%, or 20%, etc. Whenever a figure with a value of N is disclosed, any figure having a value of N+ / -1%, N+ / -2%, N+ / -3%, N+ / -5%, N+ / -7%, N+ / -8%, N+ / -10%, N+ / -15%, or N+ / -20% is explicitly disclosed, where "+ / -" indicates addition or subtraction. Whenever a lower limit, RL, and an upper limit, RU, of a numerical range are disclosed, any value within that disclosed range is explicitly disclosed. In particular, the following value is included within this range: R = RL + K * (RU - RL), where K is a variable increasing in 1% increments from 1% to 100%. For example: 1%, 2%, 3%, 4%, 5%, 50%, 51%, 52%, 95%, 96%, 97%, 98%, 99%, or 100%. In addition, the numerical ranges defined by the two R numbers disclosed herein are also specifically included.

[0035] The reagents and solvents used in this invention are all commercially available or can be prepared by the method described in this invention. Specific sources are shown in the table below: Table 1. Sources of Reagent Production

[0036] Example 1: A microemulsion of abamectin and spinosad compound The microemulsion described in Example 1 consists of the following components by mass percentage: 5 wt% ethyl spinosad, 6 wt% emamectin benzoate, 25 wt% nonionic emulsifier (18 wt% phenethylphenol polyoxypropylene polyoxyethylene block polymer 1601, 5 wt% nonionic hydroxyl polyethylene oxide block copolymer Ethylan NS-500LQ and 2 wt% Tween 80), 3 wt% anionic emulsifier (phosphate ester 1010), 20 wt% strongly polar solvent (5 wt% alcohol derivative SV-92 and 15 wt% carbonate mixture ARMID FMPC), 10 wt% weakly polar solvent (isooctyl lactate X-EHL) and 2 wt% antioxidant (2,6-di-tert-butyl-p-cresol), balance: water; The preparation method is as follows: a strong polar solvent and a weak polar solvent are mixed to obtain a compound solvent; the compound solvent is used to dissolve abamectin and spinosad technical grade, and then an antioxidant, a nonionic emulsifier and an anionic emulsifier are added. After the above system is mixed evenly, water is added and mixed evenly to obtain the final product.

[0037] Example 2: A microemulsion of abamectin and spinosad compound The microemulsion described in Example 2 is prepared in accordance with Example 1, and consists of the following components by mass percentage: 3 wt% Ethyl spinosad, 5 wt% Abamectin benzoate, 10 wt% Nonionic emulsifier (5 wt% nonionic hydroxyl polyethylene oxide block copolymer Ethylan NS-500LQ and 5 wt% Tween 80), 12 wt% Anionic emulsifier (10 wt% hexadecyl polyoxyethylene polyoxypropylene ether phosphate Crodafos C10 / 5A and 2 wt% calcium dodecylbenzenesulfonate 500#), 15 wt% Strongly polar solvent (5 wt% acetone glycerol Sunamul ACM and 10 wt% ester-amide RHODIASOLV POLARCLEAN), 10 wt% Weakly polar solvent (N,N-dimethyldecylamide 4296) and 1.5 wt% Antioxidant (2,6-di-tert-butyl-p-cresol), balance: water.

[0038] Example 3: A microemulsion of abamectin and spinosad compound The microemulsion described in Example 3 is prepared in accordance with Example 1, and consists of the following components by mass percentage: 8 wt% ethyl spinosad, 2 wt% emamectin benzoate, 17 wt% nonionic emulsifier (10 wt% arylphenol ethoxylate Emulsogen TS 200, 5 wt% nonionic hydroxyl polyethylene oxide block copolymer Ethylan NS-500LQ and 2 wt% isomeric alcohol ether Genapol XM 060), 8 wt% anionic emulsifier (hexadecyl polyoxyethylene polyoxypropylene ether phosphate Crodafos C10 / 5A), 10 wt% strongly polar solvent (5 wt% polyol ester HY-4 and 5 wt% ester-amide RHODIASOLVPOLARCLEAN), 18 wt% weakly polar solvent (octyldecamide 4166) and 1.5 wt% antioxidant (2,6-di-tert-butyl-p-cresol), balance water.

[0039] Example 4: A microemulsion of abamectin and spinosad compound The microemulsion described in Example 4 is prepared according to Example 1, and consists of the following components by mass percentage: 2.5 wt% ethyl spinosad, 5.7 wt% abamectin, 14 wt% nonionic emulsifier (2 wt% polyoxyethylene ether nonionic emulsifier YUS-CP120, 10 wt% castor oil polyoxyethylene ether nonionic emulsifier Emulpon CO 360 and 2 wt% Tween 80), 8.5 wt% anionic emulsifier (hexadecyl polyoxyethylene polyoxypropylene ether phosphate Crodafos C10 / 5A), 15.5 wt% strongly polar solvent (10.5 wt% polyol ester HY-4 and 5 wt% carbonate mixture ARMID FMPC), 10 wt% weakly polar solvent (N,N-dimethyldecylamide 4296) and 1.5 wt% antioxidant (2,6-di-tert-butyl-p-cresol), balance water.

[0040] The grouping of Examples 1-4 is as follows: Comparative Example 1: A microemulsion of emamectin benzoate and spinosad compound The difference between Comparative Example 1 and Example 4 is that the anionic emulsifier, hexadecyl polyoxyethylene polyoxypropylene ether phosphate Crodafos C10 / 5A, was replaced with the phosphate ester Emulson AG TRST.

[0041] Comparative Example 2: A microemulsion of emamectin benzoate and spinosad. The difference between Comparative Example 2 and Example 4 is that the weakly polar solvent N,N-dimethyldecanoamide 4296 was replaced with isooctyl alcohol.

[0042] Comparative Example 3: A microemulsion of emamectin benzoate and spinosad. The difference between Comparative Example 3 and Example 4 is that the weakly polar solvent N,N-dimethyldecanoamide 4296 was replaced with n-decyl alcohol.

[0043] Comparative Example 4: A microemulsion of emamectin benzoate and spinosad. The difference between Comparative Example 4 and Example 4 is that the anionic emulsifier, hexadecyl polyoxyethylene polyoxypropylene ether phosphate Crodafos C10 / 5A, was replaced with sulfate ULTRASURF 3016.

[0044] Comparative Example 5: A microemulsion of emamectin benzoate and spinosad. The difference between Comparative Example 5 and Example 4 is that the nonionic emulsifier Emulpon CO 360 was replaced with alkoxylated short-chain fatty alcohol Ethylan 992.

[0045] Comparative Example 6: A microemulsion of emamectin benzoate and spinosad. The preparation was reproduced according to the formula disclosed in the existing technology. The specific components and proportions are as follows: 3wt% abamectin, 7wt% spinosad, 7wt% methylated palm oil, 3wt% N-methylpyrrolidone, 16.7wt% EL-40 and AEO-9 (1:1 compound), 3wt% PEG-400, 2wt% Silwet L-77, 1.5wt% methylated vegetable oil (Pro-MSO), 4.0wt% propylene glycol, 0.2wt% sodium benzoate, 0.4wt% citrate-sodium citrate buffer system and 0.3wt% silicone defoamer emulsion, and then deionized water was added to make up to 100wt%.

[0046] Performance testing 1. Physical performance testing Examples 1-4 and Comparative Examples 1-6 of the present invention were used to test their appearance, dilution stability, thermal storage stability, cold storage stability, and average particle size. The specific test methods are as follows: Dilution stability: Dilute the sample 200 times in standard hard water, let it stand for 24 hours, and observe whether there is crystallization or sedimentation. Thermal storage stability: Tested according to national standard GB / T 19136-2021 "Determination of thermal storage stability of pesticides"; Cold storage stability: Tested according to national standard GB / T 19137-2003 "Determination of Low Temperature Stability of Pesticides"; Average particle size: The sample that did not crystallize after being diluted 200 times with hard water was tested according to the national standard GB / T 29022-2021 "Dynamic Light Scattering Method (DLS) for Particle Size Analysis".

[0047] The physicochemical performance test results are shown in Table 2, where the diluted states of Example 4, Comparative Example 2, and Comparative Example 3 are shown in Table 2. Figure 1 : Table 2 Physicochemical properties of Examples 1-4 and Comparative Examples 1-6

[0048] In Comparative Example 2, after replacing N,N-dimethyldecanoamide 4296 with isooctanol, the decomposition rate of abamectin reached 7.42% and the decomposition rate of ethyl spinosad reached 8.56% after 14 days of heat storage at 54°C. In Comparative Example 3, after replacing it with n-decanol, the decomposition rate of abamectin reached 9.64% and the decomposition rate of ethyl spinosad reached 6.65%. Example 4, under the same active ingredient and emulsifier conditions, showed satisfactory heat storage stability. Furthermore, the average particle sizes of Comparative Examples 2 and 3 were 39.81 nm and 37.93 nm, respectively, significantly larger than the 5.21 nm of Example 4. This result indicates that the choice of solvent directly affects the emulsification effect and the final particle size distribution. The specific solvent selection and ratio in this application, working synergistically with other components, allows the average particle size of the microemulsion to be controlled at around 5 nm, while exhibiting good heat storage stability.

[0049] In Comparative Example 1, after replacing Crodafos C10 / 5A (a phosphate ester anionic emulsifier) ​​with TRST, the microemulsion appeared transparent, but crystallization occurred after dilution 200 times in standard hard water. In Comparative Example 4, after replacing Crodafos C10 / 5A with sulfate ester 3016, the product appearance directly became cloudy. These two comparative experiments show that not all anionic emulsifiers can form an effective complex with the nonionic emulsifiers in this system. In Comparative Example 5, after replacing the nonionic emulsifier Emulpon CO 360 with Ethylan 992, the average particle size increased sharply from 5.21 nm to 502.12 nm, and stratification occurred after cold storage. The above results indicate that the specific selection and ratio of anionic and nonionic emulsifiers in this application are matched with the overall formulation system. The synergistic effect of each component ensures low interfacial tension and a high-strength microemulsion droplet interfacial film, preventing crystallization or stratification of the microemulsion during dilution or cold storage.

[0050] In summary, the microemulsion of the present invention, through the compounding of specific strong polar solvents and weak polar solvents, ensures the full dissolution of emamectin benzoate and spinosad ethyl, and prevents crystallization after dilution, providing a suitable oil phase composition for microemulsion formation. The compounding of specific anionic and nonionic emulsifiers reduces interfacial tension and makes the interfacial film of the microemulsion more stable, enabling the system to form tiny droplets of about 5 nm and maintain a dispersed state. The introduction of antioxidants inhibits the oxidative degradation of emamectin benzoate and spinosad ethyl during storage. The synergistic effect of the above components gives the microemulsion provided by the present invention excellent emulsion stability, thermal storage stability, and cold storage stability.

[0051] 2. Field efficacy trial for controlling eggplant thrips ① Test reagents Table 3 Test reagents and dosages

[0052] ② Application method During the initial peak period of eggplant thrips, use a backpack electric sprayer, diluted with 50 liters of water per acre, to evenly spray the leaves of the eggplant plants.

[0053] ③ Survey time and number of times First survey: Pre-application baseline survey, the survey period for this trial was June 6, 2025; Second survey: 1 day after drug application; the survey period for this trial was June 7, 2025. Third survey: 3 days after drug application; the survey period for this trial was June 9, 2025. Fourth survey: 7 days after drug application; the survey period for this trial was June 13, 2025. Fifth survey: 10 days after drug application. The survey period for this trial was June 16, 2025.

[0054] ④ Survey methods The survey used a five-point sampling method, taking five points in each plot, marking three eggplant plants at each point, and selecting two insect-infested leaves from the middle and upper part of each plant, for a total of 30 leaves to investigate the number of all live nymphs.

[0055] ⑤ Methods for calculating drug efficacy Insect population reduction rate (%) = (Number of insects before application - Number of insects after application) / Number of insects before application * 100%; Corrected control efficacy (%) = (Pest population reduction rate in the treated area - Pest population reduction rate in the blank control area) / (100 - Pest population reduction rate in the blank control area) * 100%.

[0056] ⑥ Test Results Table 4. Results of field efficacy trials and statistical significance of differences.

[0057] The data in the table are the average values ​​for each treatment. Statistical analysis was performed using the DPS data processing system (the conversion of the percentage of efficacy data was performed using the arcsine square root method, and the Duncan multiple range method was used for multiple comparisons. Lowercase letters represent differences at the 0.05 level, and uppercase letters represent differences at the 0.01 level).

[0058] The experiment included three dosage treatments (7.02, 8.19, and 9.36 g / ha) of the 8.2 wt% microemulsion prepared in Example 4, with 8 wt% abamectin soluble concentrate (8.4 g / ha), 60 g / L spinosad suspension concentrate (9 g / ha), and 40 wt% fluazinam·spirotetramat suspension concentrate (90 g / ha) as control agents. The corrected efficacy was investigated at 1, 3, 7, and 10 days after application.

[0059] The results showed that the microemulsion of this application exhibited a significant dose-response relationship in its control effect, with the control efficacy increasing with increasing dose at each time point. One day after application, the corrected efficacy was 76.50% for the 9.36 g / ha treatment, 73.54% for 8.19 g / ha, and 69.75% for 7.02 g / ha. Three days after application, efficacy generally increased across all treatments, reaching 86.29% for 9.36 g / ha, 82.69% for 8.19 g / ha, and 78.35% for 7.02 g / ha. Seven days after application, all treatments reached peak efficacy, with 88.72% for 9.36 g / ha, 85.32% for 8.19 g / ha, and 79.72% for 7.02 g / ha. Ten days after application, efficacy slightly decreased, but remained at 84.43% for 9.36 g / ha, 82.35% for 8.19 g / ha, and 75.35% for 7.02 g / ha. The 9.36 g / ha treatment was optimal at all time points.

[0060] Compared with the control agent, the 9.36 g / ha treatment in Example 4 showed superior control efficacy at all time points compared to both 8 wt% emamectin benzoate soluble concentrate and 60 g / L spinosad suspension concentrate, indicating a good synergistic effect between emamectin benzoate and spinosad. Compared with the commercially available compound product 40 wt% fluazinam·spirotetramat suspension concentrate, the 9.36 g / ha treatment showed slightly better or comparable control efficacy at all time points. Notably, the recommended active ingredient dosage of 8.2% emamectin benzoate·spirotetramat microemulsion (9.36 g / ha) is significantly lower than that of 40% fluazinam·spirotetramat suspension concentrate (90 g / ha), demonstrating a significant reduction in dosage and enhanced efficacy.

[0061] In terms of sustained efficacy, the 9.36 g / ha treatment achieved over 86% efficacy within 3 days after application, peaked at 88.72% within 7 days, and remained above 84% within 10 days. In summary, this application demonstrates excellent control efficacy against eggplant thrips, exhibiting both rapid and sustained effectiveness.

Claims

1. A microemulsion of emamectin benzoate and spinosad, characterized in that, By mass percentage, it includes the following components: Ethyl spinosad 2.5-8wt%, abamectin 2-6wt%, nonionic emulsifier 10-25wt%, anionic emulsifier 3-12wt%, strong polar solvent 10-20wt%, weak polar solvent 10-18wt%, and antioxidant 1.5-2wt%, with the balance being water; The nonionic emulsifier is selected from at least two of the following: phenethylphenol polyoxypropylene polyoxyethylene block polymer 1601, castor oil polyoxyethylene ether nonionic emulsifier Emulpon CO 360, nonionic hydroxyl polyethylene oxide block copolymer Ethylan NS-500LQ, polyoxyethylene ether nonionic emulsifier YUS-CP120, Tween 80, isomeric alcohol ether Genapol XM060, and arylphenol ethoxylated compound Emulsogen TS 200. The anionic emulsifier is selected from at least one of calcium dodecylbenzenesulfonate 500#, hexadecyl polyoxyethylene polyoxypropylene ether phosphate Crodafos C10 / 5A and phosphate ester 1010; The highly polar solvent is selected from at least two of the following: alcohol derivative SV-92, ester-amide RHODIASOLV POLARCLEAN, acetone glycerol succinate Sunamul ACM, carbonate mixture ARMID FMPC, and polyol ester HY-4; The weakly polar solvent is selected from at least one of N,N-dimethyldecanoamide 4296, isooctyl lactate X-EHL, and octyldecanoamide 4166; The antioxidant is 2,6-di-tert-butyl-p-cresol.

2. The microemulsion according to claim 1, characterized in that, The nonionic emulsifier is phenethylphenol polyoxypropylene polyoxyethylene block polymer 1601, nonionic hydroxyl polyethylene oxide block copolymer Ethylan NS-500LQ, and Tween 80; or... The nonionic emulsifier is a nonionic hydroxyl-containing polyethylene oxide block copolymer, Ethylan NS-500LQ, and Tween 80; or... The nonionic emulsifiers are Emulsogen TS 200, an arylphenol ethoxylated compound; Ethylan NS-500LQ, a nonionic hydroxyl polyethylene oxide block copolymer; and Genapol XM 060, an isomeric alcohol ether. or, The nonionic emulsifiers are polyoxyethylene ether nonionic emulsifier YUS-CP120, castor oil polyoxyethylene ether nonionic emulsifier Emulpon CO 360, and Tween 80.

3. The microemulsion according to claim 1, characterized in that, The highly polar solvent is an alcohol derivative SV-92 and a carbonate mixture ARMID FMPC; or, The highly polar solvent is acetone glycerol (Sunamul ACM) and ester-amide (RHODIASOLV POLARCLEAN); or... The highly polar solvent is a polyol ester HY-4 and an ester-amide RHODIASOLV POLARCLEAN; or, The highly polar solvent is a mixture of polyol ester HY-4 and carbonate ARMID FMPC.

4. The microemulsion according to any one of claims 1-3, characterized in that, The content of the ethyl spinosad is 2.5 wt%, 3 wt%, 5 wt%, or 8 wt%; and / or, The content of the emamectin benzoate is 2 wt%, 5 wt%, 5.7 wt%, or 6 wt%; and / or, The content of the nonionic emulsifier is 10wt%, 14wt%, 17wt%, or 25wt%; and / or, The content of the anionic emulsifier is 3wt%, 8wt%, 8.5wt%, or 12wt%; and / or, The content of the strongly polar solvent is 10wt%, 15wt%, 15.5wt%, or 20wt%; and / or, The content of the weakly polar solvent is 10 wt% or 18 wt%; and / or, The antioxidant content is 1.5 wt% or 2 wt%.

5. The microemulsion according to claim 1, characterized in that, By weight percentage, it comprises the following components: 2.5 wt% ethyl spinosad, 5.7 wt% abamectin, 14 wt% nonionic emulsifier, 8.5 wt% anionic emulsifier, 15.5 wt% strongly polar solvent, 10 wt% weakly polar solvent and 1.5 wt% antioxidant, with the balance being water; The nonionic emulsifiers are polyoxyethylene ether nonionic emulsifiers YUS-CP120, Tween 80, and castor oil polyoxyethylene ether nonionic emulsifier Emulpon CO 360, with a mass ratio of 1:1:

5. The anionic emulsifier is hexadecyl polyoxyethylene polyoxypropylene ether phosphate Crodafos C10 / 5A; The highly polar solvent is an ARMID FMPC mixture of polyol ester HY-4 and carbonate in a mass ratio of 2.1:

1. The weakly polar solvent is N,N-dimethyldecanoamide 4296; The antioxidant is 2,6-di-tert-butyl-p-cresol.

6. The method for preparing the microemulsion according to any one of claims 1-5, characterized in that, Includes the following steps: The abamectin and spinosad are dissolved in a mixed solution of the strong polar solvent and the weak polar solvent. Then, the antioxidant, the nonionic emulsifier and the anionic emulsifier are added and mixed evenly. Finally, water is added and mixed evenly to obtain the final product.

7. The application of the microemulsion according to any one of claims 1-5 or the microemulsion prepared by the preparation method according to claim 6 in the control of agricultural pests.

8. The application according to claim 7, characterized in that, The agricultural pests include lepidopteran larvae, coleopteran pests, and tsioptera pests.

9. The application according to claim 7 or 8, characterized in that, The total dosage of the abamectin and the spinosad is 7-10 g / ha.

Images